Last $691.00 MXN
Change Today 0.00 / 0.00%
Volume 0.0
GSKN On Other Exchanges
Symbol
Exchange
OTC US
New York
Xetra
London
Mexico
Frankfurt
As of 4:09 PM 07/22/14 All times are local (Market data is delayed by at least 15 minutes).

glaxosmithkline plc-spon adr (GSKN) Snapshot

Open
$691.00
Previous Close
$691.00
Day High
$691.00
Day Low
$691.00
52 Week High
03/4/14 - $751.50
52 Week Low
08/12/13 - $647.30
Market Cap
1.7T
Average Volume 10 Days
1.2K
EPS TTM
--
Shares Outstanding
2.4B
EX-Date
08/6/14
P/E TM
--
Dividend
$2.59
Dividend Yield
4.82%
Current Stock Chart for GLAXOSMITHKLINE PLC-SPON ADR (GSKN)

glaxosmithkline plc-spon adr (GSKN) Details

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, such as vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company provides pharmaceutical products in various therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, antibacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also offers consumer health products in total wellness, oral care, nutritional, and skin health areas. The company's total wellness products comprise Panadol for the treatment of headache and joint pain, fever, and cold symptoms; NicoDerm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to quitting smoking; and ENO Tums, a rapid relief antacid. Its oral care products include Sensodyne for the prevention of dental sensitivity; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; Aquafresh for the prevention of caries, gum disease, and bad breath; and Parodontax to help stop bleeding gums and gum health. The company’s nutrition products comprise Horlicks and Maxinutrition for nutrition; and skin health products include Physiogel, a face and body care product for dry, sensitive, and irritated skin, and Oilatum, a soothing treatment for eczema and dry skin conditions. In addition, it provides prescription medicines; and paediatric and adult vaccines against various infectious diseases. The company has a strategic cancer immunotherapy collaboration with Adaptimmune Limited to develop and commercialize NY-ESO-1 clinical cancer program. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.

99,451 Employees
Last Reported Date: 02/28/14
Founded in 1935

glaxosmithkline plc-spon adr (GSKN) Top Compensated Officers

Chief Executive Officer, Executive Director, ...
Total Annual Compensation: 2.9M GBP
Chief Financial Officer, Executive Director, ...
Total Annual Compensation: 1.6M GBP
Chairman of Global R&D & Vaccines, Executive ...
Total Annual Compensation: $3.2M
Compensation as of Fiscal Year 2013.

glaxosmithkline plc-spon adr (GSKN) Key Developments

FDA Approves GlaxoSmithKline's Flonase for Over-the-Counter Sale

GlaxoSmithKline announced that the FDA approved Flonase Allergy Relief as an over-the-counter treatment to temporarily relieve hay fever or upper respiratory allergies. The company said Flonase is the first and only over-the-counter nasal spray indicated for relief of all nasal and eye-related allergies including runny nose, sneezing, itchy nose, nasal congestion and itchy and watery eyes.

GlaxoSmithKline Submits Regulatory Application for its Malaria Vaccine Candidate, RTS,S to the European Medicines Agency

Agenus Inc. announced that GlaxoSmithKline has submitted a regulatory application for its malaria vaccine candidate, RTS,S, to the European Medicines Agency (EMA), and it has been accepted for regulatory review. RTS,S contains Agenus' QS-21 Stimulon(R) adjuvant, which is part of GSK's AS01 proprietary adjuvant system. Adjuvants can enhance the immune response when used in combination with antigens in vaccines. The Phase 3 RTS,S vaccine program was conducted at 13 African research centers in eight African countries (Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, Nigeria, and Tanzania) and included over 16,000 infants and young children. These data have been included to support the regulatory filing. The EMA submission is the first step in the regulatory process toward making the RTS,S vaccine candidate available as an addition to existing tools currently recommended for malaria prevention. An effective vaccine for use alongside other measures, such as bed nets and anti-malarial medicines, would represent an advance in malaria control. If a positive opinion from the EMA is granted, the WHO indicated that a policy recommendation may be possible by the end of 2015. A policy recommendation is a formal review process by WHO designed to assist in the development of optimal immunization schedules for diseases that have a global public health impact, such as malaria. RTS,S is the scientific name given to this malaria vaccine candidate and reflects the composition of this vaccine candidate that also contains the AS01 adjuvant system; RTS,S triggers the body's immune system to defend against the P falciparum malaria parasite when it first enters the human host's bloodstream and/or when the parasite infects liver cells; The vaccine is designed to prevent the parasite from infecting, maturing and multiplying in the liver, after which time the parasite would re-enter the bloodstream and infect red blood cells, leading to disease symptoms. In the Phase 3 efficacy trial, RTS,S was administered in three doses, one month apart.

GlaxoSmithKline plc Declares Second Interim Dividend, Payable on 2 October 2014

The Board of GlaxoSmithKline plc has declared a second interim dividend of 19 pence per share against 18 pence per share for the second quarter of 2013. The equivalent interim dividend receivable by ADR holders is 64.8204 cents per ADS based on an exchange rate of £1/$1.7058. One ADS represents two ordinary shares. The ex-dividend date will be 6 August 2014, with a record date of 8 August 2014 and a payment date of 2 October 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GSKN:MM $691.00 MXN 0.00

GSKN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $144.87 USD -0.26
Bayer AG €98.93 EUR -2.03
Gilead Sciences Inc $88.97 USD -1.57
PepsiCo Inc $91.83 USD -0.08
Sanofi €76.08 EUR -1.24
View Industry Companies
 

Industry Analysis

GSKN

Industry Average

Valuation GSKN Industry Range
Price/Earnings 15.1x
Price/Sales 2.9x
Price/Book 11.5x
Price/Cash Flow 14.9x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GLAXOSMITHKLINE PLC-SPON ADR, please visit www.gsk.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.